This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by GELLER, J. Articles by NACHTSHEIM, D. A. Search for Related Content PubMed PubMed Citation Articles by GELLER, J. Articles by NACHTSHEIM, D. A.

Tissue Dihydrotestosterone Levels and Clinical Response to Hormonal Therapy in Patients with Advanced Prostate Cancer^*

Mercy Hospital and Medical Center San Diego, California 92103

Address requests for reprints to: Dr. Jack Geller, Mercy Hospital and Medical Center, 4077 Fifth Avenue, San Diego, California 92103.

Dihydrotestosterone (DHT) levels were measured by RIA in tumor tissue from 32 men with advanced prostate cancer and correlated with their clinical responses to antiandrogen therapy. In 24 patients with tumor tissue DHT levels greater than 2.5 ng/g, 20 initially responded to therapy with partial objective regression or were objectively stable for 12 or more months, while 4 patients relapsed in less than 1 yr. The average disease-free interval in this group was 24 months, with 9 patients still continuing in partial objective regression or objective stability. Of 8 patients with DHT levels less than 2.0 ng/g, 5 had either objective progression or were objectively stable for 6 months or less; 2 other patients have completed remissions ranging from 16–24 months, while 1 patient remains objectively stable for 21 months to date. The average disease-free interval in patients with DHT levels less than 2.0 ng/g was 9.75 months, which is significantly less (P < 0.001) than that of patients with DHT levels greater than 2.5 ng/g. There was no discernible relationship between the Gleason histological grade of prostatecancer and initial clinical response to therapy in these same patients. In summary, this study supports the thesis that tissue DHT levels may be a useful marker for predicting the clinical response of prostate cancer to antiandrogen therapy.

^* This work was supported by NCI (NIH) Grant2-R 260CA-18003.

Received September 14, 1982.

This article has been cited by other articles:

				S. Rajender, K. Vijayalakshmi, S. Pooja, S. Madhavi, S. F. D. Paul, V. Vettriselvi, S. Shroff, L. Singh, and K. Thangaraj Longer (TA)n Repeat but Not A49T and V89L Polymorphisms in SRD5A2 Gene May Confer Prostate Cancer Risk in South Indian Men J Androl, November 1, 2009; 30(6): 703 - 710. [Abstract] [Full Text] [PDF]

				H. I Scher, G. Buchanan, W. Gerald, L. M Butler, and W. D Tilley Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer Endocr. Relat. Cancer, September 1, 2004; 11(3): 459 - 476. [Abstract] [Full Text] [PDF]

				M. E. Taplin and S.-M. Ho The Endocrinology of Prostate Cancer J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3467 - 3477. [Full Text] [PDF]

				E. M. John, G. G. Schwartz, D. M. Dreon, and J. Koo Vitamin D and Breast Cancer Risk: The NHANES I Epidemiologic Follow-up Study, 1971-1975 to 1992 Cancer Epidemiol. Biomarkers Prev., May 1, 1999; 8(5): 399 - 406. [Abstract] [Full Text]